Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | ACLY | P53396 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
| ▸ | ACACA | Q13085 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6835334 | 0.83 | TSHR (0.39) | TSHRALDH1A1CYP2D6CYP2C19HIF1A | |
| SCHEMBL2203061 | 0.83 | MAPT (0.31) | — | |
| SCHEMBL2580539 | 0.81 | — | — | |
| SCHEMBL31637479 | 0.81 | LMNA (0.31) | — | |
| SCHEMBL30656499 | 0.81 | ALDH1A1 (0.35) | TSHRALDH1A1 | |
| SCHEMBL27192544 | 0.79 | ACLY (0.37) | CYP2C9ACLYTSHRACACBACACA | |
| SCHEMBL30656396 | 0.79 | — | — | |
| SCHEMBL979250 | 0.79 | GGT1 (0.38) | ALDH1A1 | |
| SCHEMBL769048 | 0.79 | DGAT1 (0.37) | DGAT1 | |
| SCHEMBL979248 | 0.79 | GGT1 (0.38) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250206756-A1 | INHIBITORS | PFIZER INC. (US) | 2025-06-26 | — | — | US | disclosed |
| WO-2025133948-A1 | ACETYL COA-CARBOXYLASE (ACC) INHIBITORS | PFIZER INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20180303864-A1 | POLYNUCLEOTIDES HAVING BIOREVERSIBLE GROUPS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-10-25 | — | — | US | disclosed |
| US-9950001-B2 | Polynucleotides having bioreversible groups | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-04-24 | — | — | US | disclosed |
| US-9950001-B2 | Polynucleotides having bioreversible groups | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-04-24 | — | — | US | disclosed |
| US-20150238516-A1 | POLYNUCLEOTIDES HAVING BIOREVERSIBLE GROUPS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-08-27 | — | — | US | disclosed |
| US-20150238516-A1 | POLYNUCLEOTIDES HAVING BIOREVERSIBLE GROUPS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-08-27 | — | — | US | disclosed |
| US-20150238516-A1 | POLYNUCLEOTIDES HAVING BIOREVERSIBLE GROUPS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-08-27 | — | — | US | disclosed |
| EP-2885313-A1 | POLYNUCLEOTIDES HAVING BIOREVERSIBLE GROUPS | The Regents of The University of California (US) | 2015-06-24 | — | — | EP | disclosed |
| US-8912338-B2 | Pesticidal compositions | Dow AgroScience, LLC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-20090082440-A1 | SIMPLE PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. | 2009-03-26 | — | — | US | disclosed |
| US-20090076147-A1 | COMPLEX PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. | 2009-03-19 | — | — | US | disclosed |
| WO-2009033054-A1 | COMPLEX PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009033061-A1 | MASKED CARBOXYLATE NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009033069-A1 | SIMPLE PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2009-03-12 | — | — | WO | disclosed |
| US-20090069419-A1 | MASKED CARBOXYLATE NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. | 2009-03-12 | — | — | US | disclosed |
| WO-2009015000-A1 | PYRAZOLE UREA DERIVATIVES USED AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-01-29 | — | — | WO | disclosed |
| US-20080194576-A1 | Pyrimidine Derivatives and Their Use as P2Y12 Receptor Antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-08-14 | — | — | US | disclosed |
| EP-1893634-A2 | PYRIMIDINE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006114774-A2 | PYRIMIDINE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069419-A1 | MASKED CARBOXYLATE NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | ADSL, AASDHPPT, ACMSD | CYP2C9 340/4885ACLY 395/4885TSHR 2626/4885 |
| US-20180303864-A1 | POLYNUCLEOTIDES HAVING BIOREVERSIBLE GROUPS | RNASE1, NCL, LNPEP | CYP2C9 4615/4885ACLY 3469/4885TSHR 3732/4885 |
| US-20090076147-A1 | COMPLEX PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | ADSL, SLC19A1, SLC25A21 | CYP2C9 359/4885ACLY 253/4885TSHR 2112/4885 |
| US-20080194576-A1 | Pyrimidine Derivatives and Their Use as P2Y12 Receptor Antagonists | P2RY12, P2RY13, P2RY4 | CYP2C9 1012/4885ACLY 3480/4885TSHR 1238/4885 |
| US-20250206756-A1 | INHIBITORS | CUTA, SERPINB1, SERPINE1 | CYP2C9 2018/4885ACLY 327/4885TSHR 4288/4885 |
| US-20090082440-A1 | SIMPLE PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | ADSL, SLC19A1, SLC25A21 | CYP2C9 400/4885ACLY 247/4885TSHR 1953/4885 |
| US-20150238516-A1 | POLYNUCLEOTIDES HAVING BIOREVERSIBLE GROUPS | RNASE1, NCL, LNPEP | CYP2C9 4615/4885ACLY 3469/4885TSHR 3732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.